Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Showing 1 to 12 of 230 entries
Sorted by: Best Match Show Resources per page
The cost of developing new drugs.

Oncology (Williston Park, N.Y.)

[No authors listed]
PMID: 1531601
Oncology (Williston Park). 1992 Jan;6(1):142-3.

No abstract available.

Designing drugs.

British journal of hospital medicine

Calvey TN.
PMID: 1591555
Br J Hosp Med. 1992 Apr 15-May 5;47(8):567-9.

No abstract available.

DNA and associated targets for drug design.

Journal of medicinal chemistry

Hurley LH.
PMID: 2671370
J Med Chem. 1989 Sep;32(9):2027-33. doi: 10.1021/jm00129a001.

No abstract available.

Computation space.

Journal of computer-aided molecular design

Counts RW.
PMID: 2092085
J Comput Aided Mol Des. 1990 Dec;4(4):427-8. doi: 10.1007/BF00117407.

No abstract available.

Proteomics: applications and opportunities in preclinical drug development.


Steiner S, Witzmann FA.
PMID: 10892720
Electrophoresis. 2000 Jun;21(11):2099-104. doi: 10.1002/1522-2683(20000601)21:11<2099::AID-ELPS2099>3.0.CO;2-N.

Advances in DNA sequencing and the near-term availability of whole genome sequences for several pharmaceutically relevant organisms promise to dramatically alter the breadth and scale of high-throughput proteomic studies. The substantial amount of literature is available in the public...

The use of chemical design tools to transform proteomics data into drug candidates.


Dean PM, Zanders ED.
PMID: 11906004
Biotechniques. 2002 Mar;28-33.

The Human Genome Project has fueled the massive information-driven growth of genomics and proteomics and promises to deliver new insights into biology and medicine. Since proteins represent the majority of drug targets, these molecules are the focus of activity...

[Effective paradigms in drug discovery: integration of combinatorial chemistry with rational drug design].

Yao xue xue bao = Acta pharmaceutica Sinica

Li WZ, Yun LH.
PMID: 12016878
Yao Xue Xue Bao. 1998 Sep;33(9):710-6.

No abstract available.

How to escape the bottleneck of medicinal chemistry.

Drug discovery today

Wess G.
PMID: 12047844
Drug Discov Today. 2002 May 15;7(10):533-5. doi: 10.1016/s1359-6446(02)02252-3.

No abstract available.

[The comparative analysis of alternatives for university industry relations].

Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme

Kano S.
PMID: 10771653
Tanpakushitsu Kakusan Koso. 2000 Apr;45(6):928-34.

No abstract available.

The importance of predictive ADME simulation.

Drug discovery today

Dickins M, Modi S.
PMID: 12547029
Drug Discov Today. 2002 Jul 15;7(14):755-6. doi: 10.1016/s1359-6446(02)02357-7.

No abstract available.

Structure-based screening of low-affinity compounds.

Drug discovery today

Carr R, Jhoti H.
PMID: 11983569
Drug Discov Today. 2002 May 01;7(9):522-7. doi: 10.1016/s1359-6446(02)02245-6.

Conventional bioassay-based screening remains a mainstream approach for lead discovery. However, its limitations have meant that other, more biophysical methods, such as X-ray crystallography and NMR, are now being developed as lead discovery tools. These methods are particularly effective...

A call to arms for drug discoverers.

Nature reviews. Drug discovery

[No authors listed]
PMID: 12755124
Nat Rev Drug Discov. 2003 May;2(5):335. doi: 10.1038/nrd1097.

No abstract available.

Showing 1 to 12 of 230 entries